Fol. Biol. 2024, 70, 239-247
https://doi.org/10.14712/fb2024070050239
Dyslipidaemia in Liver Diseases
References
1. , Y., Seki, N., Nagano, T. et al. (2015) Chronic hepatitis virus infection and lipoprotein metabolism. World J. Gastroenterol. 21, 10299-10313.
<https://doi.org/10.3748/wjg.v21.i36.10299>
2. , M. I. K., Kazmi, A., Haider, I. et al. (2016) Correlation of duration of hepatitis C infection with triglycerides and total cholesterol. J. Islamabad Med. Dent. Coll. 5, 168-171.
3. , M., Laranjeira, F., Correia-da-Silva, G. (2024) Understanding hypertriglyceridemia: integrating genetic insights. Genes (Basel) 15, 190.
<https://doi.org/10.3390/genes15020190>
4. , P., Perlemuter, G., Budkowska, A. et al. (2005) Hepatitis C virus particles and lipoprotein metabolism. Semin. Liver Dis. 5, 93-104.
<https://doi.org/10.1055/s-2005-864785>
5. Arvind, A., Osganian, S. A., Cohen, D. E. et al. (2019 [Updated 2019 Jul 21]) Lipid and lipoprotein metabolism in liver disease. In: Endotext [Internet], eds. Feingold, K. R., Anawalt, B., Blackman, M. R. et al., South Dartmouth (MA): MDText.com, Inc.; 2000. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK326742/
6. , A. J., Hegele, R. A. (2022) A modern approach to dyslipidemia. Endocr. Rev. 43, 611-653.
<https://doi.org/10.1210/endrev/bnab037>
7. , L., Bassani, L., Marroni, C. A. et al. (2015) Lipid profile in cirrhotic patients and its relation to clinical outcome. Arq. Bras. Cir. Dis. 28, 132-135.
<https://doi.org/10.1590/s0102-67202015000200012>
8. Brewer, H. B. Jr. (2015) High density lipoprotein metabolism. In: Clinical Lipidology. A Companion to BraunwARLD’s Heart Disease, ed. Ballantyne, C. M., pp. 43-51, 2nd ed. Elsevier, Philadelphia.
9. , E. A. (2012) Effects of ethanol intake on lipoproteins. Curr. Atheroscler. Rep. 14, 108-114.
<https://doi.org/10.1007/s11883-012-0230-7>
10. , L., Giannakodimos, I., Diamantopoulou, P. et al. (2022) Non-alcoholic fatty liver disease and hepatocellular carcinoma: clinical challenges of an intriguing link. World J. Gastroenterol. 28, 310-331.
<https://doi.org/10.3748/wjg.v28.i3.310>
11. , C., Malavolti, M., Morselli-Labate, A. M. et al. (1997) Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch. Intern. Med. 157, 792-796.
<https://doi.org/10.1001/archinte.1997.00440280120012>
12. , K. E., Chalasani, N. (2014) Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12, 1077-1084.
<https://doi.org/10.1016/j.cgh.2013.08.014>
13. , M. A. (2013) Lipoprotein X: clinical implications. Ann. Clin. Biochem. 50, 93-94.
<https://doi.org/10.1177/0004563213478804>
14. , L., Hmood, A. R., Dahalemi, A. K. et al. (2020) Dyslipidemia in patients with hepatitis C virus infection. Ann. Tropic. Med. Health 23, 23-941.
15. , A., Tietge, U. J. F. (2010) Biliary cholesterol secretion: more than a simple ABC. World J. Gastroenterol. 16, 5936-5945.
16. , J. S., Hegele, R. A. (2020) Genetics of hypertriglyceridemia. Front. Endocrinol. 11, 455.
<https://doi.org/10.3389/fendo.2020.00455>
17. , B., Bataller, R. (2011) Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141, 1572-1585.
<https://doi.org/10.1053/j.gastro.2011.09.002>
18. , J., Lee, S.-G., Kim, J.-H. (2017) Lipoprotein X detected in a case of hypercholesterolemia associated with chronic cholangiohepatitis. Ann. Lab. Med. 37, 550-552.
<https://doi.org/10.3343/alm.2017.37.6.550>
19. , S. K., Baik, S. K., Kim, M. Y. (2023) Non-alcoholic fatty liver disease: definition and subtypes. Clin. Mol. Hepatol. 29(Suppl.), S5-S16.
<https://doi.org/10.3350/cmh.2022.0424>
20. , J., Yang, T., Zhou, Y. (2017) Serum metabolomics analysis reveals a distinct metabolic profile of patients with primary biliary cholangitis. Sci. Rep. 7, 784.
<https://doi.org/10.1038/s41598-017-00944-9>
21. , J., Scheja, L. (2021) Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol. Metab. 50, 101238.
<https://doi.org/10.1016/j.molmet.2021.101238>
22. Herink, M., Ito, M. K., Feingold, K. R. et al. [Updated 2018 May 10] Medication induced changes in lipid and lipoproteins. In: Endotext [Internet], eds. Feingold, K. R., Anawalt, B., Blackman, M.R. et al., South Dartmouth (MA): MDText.com, Inc.; 2000. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK326739/
23. , T. (2018) Pathophysiology of diabetic dyslipidemia. J. Atheroscler. Thromb. 25, 771-782.
<https://doi.org/10.5551/jat.RV17023>
24. , R. C., Gaubatz, J. W., Sun, W. et al. (2014) Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscl. Thromb. Vasc. Biol. 34, 1069-1077.
<https://doi.org/10.1161/ATVBAHA.114.303284>
25. , J., Han, J., Lee, C. et al. (2021) Pathophysiological aspects of alcohol metabolism in the liver. Int. J. Mol. Sci. 22, 5717.
<https://doi.org/10.3390/ijms22115717>
26. , S., Rasheed, A., Jabeen, N. et al. (2020) Prevalence and association of HBV and HCV infection with cardiovascular disease risk factors in a peri-urban population. J. Pak. Med. Assoc. 70, 58-63.
27. , S., Carr, R. (2020) Alcohol effects on hepatic lipid metabolism. J. Lipid Res. 61, 470-479.
<https://doi.org/10.1194/jlr.R119000547>
28. , P., Martin, A., Lang, S. et al. (2021) NAFLD and cardiovascular diseases: a clinical review. Clin. Res. Cardiol. 110, 921-937.
<https://doi.org/10.1007/s00392-020-01709-7>
29. , S. H., Park, S.-Y., Choi, C. S. (2022) Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab. J. 46, 15-37.
<https://doi.org/10.4093/dmj.2021.0280>
30. , G. F., Xiao, C., Hegele, R. A. (2015) Hypertriglyceridemia in the genomic era: a new paradigm. Endocr. Rev. 36, 131-147.
<https://doi.org/10.1210/er.2014-1062>
31. , S., Taskinen, M.-R., Borén, J. (2019) Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes. Rev. 20, 599-611.
<https://doi.org/10.1111/obr.12820>
32. , K. D., Gershwin, M. E., Poupon, R. et al. (2009) Primary biliary cirrhosis. Hepatology 50, 291-308.
<https://doi.org/10.1002/hep.22906>
33. , K. D., Kowdley, K. V., Harrison, M. E. (2015) ACG clinical guideline: primary sclerosing cholangitis. Am. J. Gastroenterol. 110, 646-659.
<https://doi.org/10.1038/ajg.2015.112>
34. , P., Marchesini, G., Nascimbeni, F. et al. (2014) Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 232, 99-109.
<https://doi.org/10.1016/j.atherosclerosis.2013.10.030>
35. , E., Fellin, R., Baggio, G. et al. (1976) Formation of lipoprotein-X. Its relationship to bile compounds. J. Clin. Invest. 57, 1248-1260.
<https://doi.org/10.1172/JCI108393>
36. , F. (2022) NAFLD: mechanisms, treatments, and biomarkers. Biomolecules 12, 824.
<https://doi.org/10.3390/biom12060824>
37. , K., Aberg, F., Gylling, H. et al. (2016) Cholesterol metabolism in cholestatic liver disease and liver transplantation: from molecular mechanisms to clinical implications. World J. Hepatol. 8, 924-932.
<https://doi.org/10.4254/wjh.v8.i22.924>
38. , R. S., Dasarathy, S., McCullough, A. J. (2010) Alcoholic liver disease. Hepatology 51, 307-328.
<https://doi.org/10.1002/hep.23258>
39. , N. A., Donohue, M. T., Kharbanda, K. K. (2017) Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 38, 147-161.
40. , C. J., Boren, J., Taskinen, M. R. (2020) Causes and consequences of hypertriglyceridemia. Front. Endocrinol. 11, 532994.
<https://doi.org/10.3389/fendo.2020.00252>
41. , M. C., Sandhu, B., Bonder, A. et al. (2019) Lipoprotein metabolism in liver diseases. Curr. Opin. Lipidol. 30, 30-36.
<https://doi.org/10.1097/MOL.0000000000000569>
42. , B. J., Khan, M. A., Yoo, E. R. et al. (2017) Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J. Gastroenterol. 23, 8263-8276.
<https://doi.org/10.3748/wjg.v23.i47.8263>
43. , M. C., Shulman, G. I. (2018) Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133-2223.
<https://doi.org/10.1152/physrev.00063.2017>
44. , D. V., Zemlin, A. E. (2015) Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis. Ann. Hepatol. 6, 924-928.
<https://doi.org/10.5604/16652681.1171785>
45. Pownal, H. J., Rosales, C., Gillard, B. K. et al. (2015) Human plasma lipoprotein metabolism. In: Clinical Lipidology. A Companion to BraunwARLD’s Heart Disease, ed. Ballantyne, C. M., pp. 1-10, 2nd ed. Elsevier, Philadelphia.
46. , G., Spadaro, L., Marchisello, S. et al. (2018) Abnormalities of lipoprotein levels in liver cirrhosis: clinical relevance. Dig. Dis. Sci. 63, 16-26.
<https://doi.org/10.1007/s10620-017-4862-x>
47. , V. I. (2012) Concept of the pathogenesis and treatment of cholelithiasis. World J. Hepatol. 27, 18-34.
<https://doi.org/10.4254/wjh.v4.i2.18>
48. Roy-Chowdhury, N., Roy-Chowdhury, J. (2010) Liver physiology and energy metabolism. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease-2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition-Enhanced Online Features and Print, eds. Feldman, M., Friedman, L. S., Brandt, L. J., pp. 1207-1225, 9th ed. Elsevier, Philadelphia.
49. , D. W., Setchell, K. D. (1992) Bile acid biosynthesis. Biochemistry 31, 4737-4749.
<https://doi.org/10.1021/bi00135a001>
50. , C., Gaggini, M., Carli, F. et al. (2015) The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis. Nutrients 7, 9453-9474.
<https://doi.org/10.3390/nu7115475>
51. , E., Anstee, Q. M. (2018) Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clin. Med. (Lond.) 18(Suppl. 2), s54-s59.
<https://doi.org/10.7861/clinmedicine.18-2-s54>
52. , E. K., Balakrishnan, M., Friedman, L. S. et al. (2018) Treatment of dyslipidemia in common liver diseases. Clin. Gastroenterol. Hepatol. 16, 1189-1196.
<https://doi.org/10.1016/j.cgh.2018.04.023>
53. , G. G., Pan, K. H., Zhao, N. F. et al. (2004) Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J. Gastroenterol. 10, 910-912.
<https://doi.org/10.3748/wjg.v10.i6.910>
54. , L., Hirayama, S., Fukui, M. et al. (2017) Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages. J. Clin. Lipidol. 11, 110-118.
<https://doi.org/10.1016/j.jacl.2016.10.013>
55. , G., Day, C. P., Bonora, E. (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341-1350.
<https://doi.org/10.1056/NEJMra0912063>
56. , M. R., Borén, J. (2015) New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239, 483-495.
<https://doi.org/10.1016/j.atherosclerosis.2015.01.039>
57. , A. (2012) The effect of alcohol on postprandial and fasting triglycerides. Int. J. Vasc. Med. 1, 862504.
58. WHO (2023) No level of alcohol consumption is safe for our health 2023. Retrieved from: https://www.who.int/europe/news/item/04-01-2023-no-level-of-alcohol-consumption-is-safe-for-our-health
59. , X., Chen, K., Williams, K. J. (2012) The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia. Curr. Opin. Lipidol. 23, 334-344.
<https://doi.org/10.1097/MOL.0b013e3283544424>
60. , Y. H., Tsan, Y. T., Chen, M. J. et al. (2015) Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J. Hepatol. 63, 1111-1117.
<https://doi.org/10.1016/j.jhep.2015.07.006>
61. , M., Arteel, G. E. (2019) Effect of ethanol on lipid metabolism. J. Hepatol. 70, 237-248.
<https://doi.org/10.1016/j.jhep.2018.10.037>
62. , C., Huai, Q., Zhang, X. et al. (2023) Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease. Int. J. Biol. Sci. 19, 311-330.
<https://doi.org/10.7150/ijbs.78525>
63. , A., Jáchymová, M., Tvrzická, E. et al. (2008) The influence of polymorphism of −493G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stress. J. Nutr. Biochem. 9, 634-641.
<https://doi.org/10.1016/j.jnutbio.2007.09.001>
